Ajanta Pharma Launches Met-XL D to Improve Outcomes for Heart Failure and Post-Myocardial Infarction Patients
Ajanta Pharma, one of the leaders in the cardiology segment has launched the fixed dose combination of Metoprolol and Dapagliflozin under the brand name Met XL D. Met XL D is indicated for patients with heart failure, post myocardial infarction, and individuals at high cardiovascular disease risk.
Met XL D is a fixed-dose combination tablet of Metoprolol Extended Release, a beta-blocker, and Dapagliflozin, an SGLT2 inhibitor. It is available in two dosage strengths and contains Metoprolol 25 mg with Dapagliflozin 10 mg, or Metoprolol 50 mg with Dapagliflozin 10 mg.
The American College of Cardiology guidelines mention a Class 1a recommendation for beta-blockers and SGLT2 inhibitors in heart failure with reduced ejection fraction (HFrEF) to reduce mortality and hospitalizations. The European Society of Cardiology guidelines suggest a Class 1a recommendation for SGLT2 inhibitors and a Class 2b recommendation for beta-blockers in heart failure with mildly reduced ejection fraction (HFmrEF).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.